drugset
drugset / Trial / NCT00673439

Fondaparinux for the Treatment of Heparin-Induced Thrombocytopenia (HIT)

NCT00673439 ↗

Phase 2 Terminated 3 enrolled University of Louisville James Graham Brown Cancer Center · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine how safe and effective fondaparinux is in treating patients with suspected or confirmed heparin-induced thrombocytopenia (HIT).

Timeline

Start
2007-11
Primary completion
2011-09
Completion
2011-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Fondaparinux Other / unclassified 7.5 mg Subcutaneous
Subject Fondaparinux Other / unclassified 10 mg Subcutaneous
Background Warfarin Small molecule 2.5 mg Oral
Background Warfarin Small molecule 5 mg Oral

Indications

heparin-induced thrombocytopenia